Oncolytics Biotech Files 6-K

Ticker: ONCY · Form: 6-K · Filed: Feb 25, 2025 · CIK: 1129928

Sentiment: neutral

Topics: foreign-private-issuer, reporting, sec-filing

TL;DR

ONCOLYTICS BIOTECH (ONCY) filed a 6-K, confirming Canadian base and 20-F reporting.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on February 25, 2025, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations industry. This filing is for the month of February 2025 and indicates they file annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for foreign private issuers, informing investors about their reporting status and location.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the primary purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, typically to provide information that the issuer makes or is required to make public in its home country.

Where is Oncolytics Biotech Inc. located?

Oncolytics Biotech Inc. is located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.

Under which form does Oncolytics Biotech Inc. file its annual reports?

Oncolytics Biotech Inc. files its annual reports under cover of Form 20-F.

What is the Standard Industrial Classification code for Oncolytics Biotech Inc.?

The Standard Industrial Classification code for Oncolytics Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the SEC file number for Oncolytics Biotech Inc.?

The SEC file number for Oncolytics Biotech Inc. is 001-38512.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on February 25, 2025 regarding ONCOLYTICS BIOTECH INC (ONCY).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing